Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can
stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight
prostate cancer by reducing the production of androgens. It is not yet known if radiation
therapy is more effective with or without bicalutamide for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or
without bicalutamide in treating patients who have stage II or stage III prostate cancer and
elevated prostate-specific antigen (PSA) levels following radical prostatectomy.
Phase:
Phase 3
Details
Lead Sponsor:
Radiation Therapy Oncology Group
Collaborators:
National Cancer Institute (NCI) NRG Oncology Southwest Oncology Group